Pfizer (NYSE:PFE – Get Rating) had its price target lifted by investment analysts at Barclays from $50.00 to $52.00 in a report issued on Monday, The Fly reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective points to a potential upside of 4.65% from the stock’s previous close.
Other research analysts also recently issued research reports about the company. The Goldman Sachs Group set a $50.00 price objective on Pfizer in a report on Friday, July 29th. Citigroup increased their price target on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Morgan Stanley cut their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research note on Friday, July 8th. Wells Fargo & Company cut their price target on Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Finally, JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, June 28th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $57.50.
Pfizer Trading Down 1.8 %
PFE stock opened at $49.69 on Monday. Pfizer has a 1-year low of $40.94 and a 1-year high of $61.71. The firm has a market cap of $278.81 billion, a P/E ratio of 9.72, a P/E/G ratio of 0.62 and a beta of 0.67. The business’s 50 day moving average is $51.34 and its 200-day moving average is $51.18. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43.
Insider Transactions at Pfizer
In other news, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock worth $2,075,003 in the last 90 days. Corporate insiders own 0.05% of the company’s stock.
Institutional Investors Weigh In On Pfizer
Large investors have recently added to or reduced their stakes in the business. Steward Financial Group LLC grew its holdings in Pfizer by 315.3% in the 2nd quarter. Steward Financial Group LLC now owns 544 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 413 shares in the last quarter. Worth Asset Management LLC acquired a new position in Pfizer in the 1st quarter valued at $29,000. PYA Waltman Capital LLC acquired a new position in Pfizer in the 4th quarter valued at $31,000. Rinkey Investments acquired a new position in Pfizer in the 4th quarter valued at $32,000. Finally, Stuart Chaussee & Associates Inc. grew its holdings in Pfizer by 108.3% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 325 shares in the last quarter. Institutional investors own 66.50% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
- Are Baidu’s Delisting Fears a Good Entry for New Investors?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.